Patents by Inventor Franco Venanzi

Franco Venanzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220009985
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 13, 2022
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 11098098
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 24, 2021
    Assignee: CureLab Oncology, Inc.
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Publication number: 20200338176
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 29, 2020
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Patent number: 10716837
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: July 21, 2020
    Assignee: CURELAB ONCOLOGY, INC.
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Publication number: 20190153056
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: October 22, 2018
    Publication date: May 23, 2019
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 9717781
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: August 1, 2017
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Publication number: 20170043002
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Publication number: 20160324944
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: December 29, 2014
    Publication date: November 10, 2016
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Publication number: 20140161824
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Application
    Filed: August 8, 2012
    Publication date: June 12, 2014
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Patent number: 6127344
    Abstract: Polynucleotide immunogenic agents capable of inducing an immune response towards the members of the Epidermal Growth Factor Receptors (EGFR) family are disclosed.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: October 3, 2000
    Assignee: Universita' Degli Studi di Camerino
    Inventors: Augusto Amici, Antonio Concetti, Franco Venanzi